FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313593746> ?p ?o ?g. }

• W4313593746 endingPage "109657" @default.
• W4313593746 startingPage "109657" @default.
• W4313593746 abstract "Immune checkpoint inhibitors (ICIs) have entered the treatment paradigm for unresectable advanced melanoma, but there is a lack of evidence regarding its relative efficacy and safety. This study aim to compare the efficacy and safety of ICIs in patients with advanced unresectable melanoma.Studies included randomized clinical trials (RCTs) that compared ICIs, or combination therapy of ICIs, or with chemotherapy drugs, different ICIs, or one of the ICIs at different dosing schedules. Random-effects models of Bayesian network meta-analysis were performed following the PRISMA reporting guideline. Primary outcomes were overall survival (OS) and progression-free survival (PFS). Secondary outcomes included objective response rate (ORR), disease control rate (DCR), and adverse events.CRD42021229086.Twenty-four RCTs with 18 different treatment regimens for advanced melanoma involving 10,090 patients were included. Overall, nivolumab 1 mg/kg plus ipilimumab 3 mg/kg treatment regimen were associated with the highest beneficial effect on OS, PFS, and DCR. Closely followed by nivolumab 3 mg/kg plus ipilimumab 1 mg/kg, and nivolumab plus relatlimab treatment regimens. However, three regimens had less favorable safety profiles. Although ipilimumab 0.3 mg/kg was ranked as the best options with the lowest risk of grade ≥ 3 treatment or immune-related adverse events, less therapeutic benefit was performed. The pembrolizumab 10 mg/kg regimen may be the preferred treatment with relative higher efficiency and safety among the ICIs regimens reported, as well as the nivolumab 3 mg/kg regimen. Head-to-head trials showed similar results.This study shown the preferred treatment regimens with relatively higher efficiency and safety among the reported ICI regimens. Our results may complement the current standard of care, while its direct drug comparisons will aid future trials." @default.
• W4313593746 created "2023-01-06" @default.
• W4313593746 creator A5010236351 @default.
• W4313593746 creator A5038805449 @default.
• W4313593746 creator A5043094856 @default.
• W4313593746 creator A5065722429 @default.
• W4313593746 date "2023-02-01" @default.
• W4313593746 modified "2023-10-16" @default.
• W4313593746 title "Comparative efficacy and safety of immune checkpoint inhibitors for unresectable advanced melanoma: A systematic review and network meta-analysis" @default.
• W4313593746 cites W1967385770 @default.
• W4313593746 cites W1990675339 @default.
• W4313593746 cites W2038325530 @default.
• W4313593746 cites W2040851929 @default.
• W4313593746 cites W2074546881 @default.
• W4313593746 cites W2088095316 @default.
• W4313593746 cites W2095826876 @default.
• W4313593746 cites W2097995306 @default.
• W4313593746 cites W2123363005 @default.
• W4313593746 cites W2136746908 @default.
• W4313593746 cites W2138134458 @default.
• W4313593746 cites W2166662937 @default.
• W4313593746 cites W2413861456 @default.
• W4313593746 cites W2519279652 @default.
• W4313593746 cites W2527038934 @default.
• W4313593746 cites W2540613192 @default.
• W4313593746 cites W2603690292 @default.
• W4313593746 cites W2611414538 @default.
• W4313593746 cites W2726861941 @default.
• W4313593746 cites W2747107882 @default.
• W4313593746 cites W2753432434 @default.
• W4313593746 cites W2763265527 @default.
• W4313593746 cites W2766729634 @default.
• W4313593746 cites W2792937256 @default.
• W4313593746 cites W2795136738 @default.
• W4313593746 cites W2797675588 @default.
• W4313593746 cites W2808750176 @default.
• W4313593746 cites W2810896552 @default.
• W4313593746 cites W2896600825 @default.
• W4313593746 cites W2898510820 @default.
• W4313593746 cites W2915708315 @default.
• W4313593746 cites W2948740360 @default.
• W4313593746 cites W2949375297 @default.
• W4313593746 cites W2982112607 @default.
• W4313593746 cites W3013344454 @default.
• W4313593746 cites W3016997444 @default.
• W4313593746 cites W3034459487 @default.
• W4313593746 cites W3113132520 @default.
• W4313593746 cites W3167529791 @default.
• W4313593746 cites W4206841660 @default.
• W4313593746 cites W4225394054 @default.
• W4313593746 cites W4229069946 @default.
• W4313593746 cites W4291130566 @default.
• W4313593746 doi "https://doi.org/10.1016/j.intimp.2022.109657" @default.
• W4313593746 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36608446" @default.
• W4313593746 hasPublicationYear "2023" @default.
• W4313593746 type Work @default.
• W4313593746 citedByCount "4" @default.
• W4313593746 countsByYear W43135937462023 @default.
• W4313593746 crossrefType "journal-article" @default.
• W4313593746 hasAuthorship W4313593746A5010236351 @default.
• W4313593746 hasAuthorship W4313593746A5038805449 @default.
• W4313593746 hasAuthorship W4313593746A5043094856 @default.
• W4313593746 hasAuthorship W4313593746A5065722429 @default.
• W4313593746 hasConcept C121608353 @default.
• W4313593746 hasConcept C126322002 @default.
• W4313593746 hasConcept C143998085 @default.
• W4313593746 hasConcept C168563851 @default.
• W4313593746 hasConcept C197934379 @default.
• W4313593746 hasConcept C2777658100 @default.
• W4313593746 hasConcept C2777701055 @default.
• W4313593746 hasConcept C2780030458 @default.
• W4313593746 hasConcept C2780057760 @default.
• W4313593746 hasConcept C2781413609 @default.
• W4313593746 hasConcept C2781433595 @default.
• W4313593746 hasConcept C502942594 @default.
• W4313593746 hasConcept C71924100 @default.
• W4313593746 hasConceptScore W4313593746C121608353 @default.
• W4313593746 hasConceptScore W4313593746C126322002 @default.
• W4313593746 hasConceptScore W4313593746C143998085 @default.
• W4313593746 hasConceptScore W4313593746C168563851 @default.
• W4313593746 hasConceptScore W4313593746C197934379 @default.
• W4313593746 hasConceptScore W4313593746C2777658100 @default.
• W4313593746 hasConceptScore W4313593746C2777701055 @default.
• W4313593746 hasConceptScore W4313593746C2780030458 @default.
• W4313593746 hasConceptScore W4313593746C2780057760 @default.
• W4313593746 hasConceptScore W4313593746C2781413609 @default.
• W4313593746 hasConceptScore W4313593746C2781433595 @default.
• W4313593746 hasConceptScore W4313593746C502942594 @default.
• W4313593746 hasConceptScore W4313593746C71924100 @default.
• W4313593746 hasFunder F4320321001 @default.
• W4313593746 hasLocation W43135937461 @default.
• W4313593746 hasLocation W43135937462 @default.
• W4313593746 hasOpenAccess W4313593746 @default.
• W4313593746 hasPrimaryLocation W43135937461 @default.
• W4313593746 hasRelatedWork W2155654588 @default.
• W4313593746 hasRelatedWork W2466451466 @default.
• W4313593746 hasRelatedWork W2475687906 @default.
• W4313593746 hasRelatedWork W2580215808 @default.

• next